IMGS-001 by Immunogenesis for Bladder Cancer: Likelihood of Approval

Brought to you by GlobalData


IMGS-001 is under clinical development by Immunogenesis and currently in Phase I for Bladder Cancer. According to GlobalData, Phase I drugs for Bladder Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IMGS-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IMGS-001 overview

IMGS-001 is under development for the treatment of  metastatic solid tumors, ovarian cancer, prostate, colorectal, triple-negative breast cancer, gastroesophageal junction adenocarcinoma, bladder cancer, esophageal cancer, bladder cancer and pancreatic cancer. The drug candidate is a dual specific checkpoint inhibitor and tumor microenvironment (TME) remodeling agent. It is a bi-specific monoclonal antibody acts by targeting programmed cell death protein 1 (PD-1), programmed cell death 1 ligand 1 and 2 and cytotoxic T lymphocyte protein 4 (CTLA-4).

Immunogenesis overview

Immunogenesis is a developer of immuno-oncology therapeutics intended to create anti-tumor immunity against cold cancers. The company is headquartered in Houston, Texas, The US.

For a complete picture of IMGS-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.

More Relevant


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.